|1||NCT03864185||Recruiting||The Evaluation of Efficacy and Safety of Rituximab in Refractory CIDP Patients With IgG4 Autoantibodies||
||Other / Industry||
||25||All||12 Years and older (Child, Adult, Older Adult)||NCT03864185||CAMCR-011
|RECIPE||March 28, 2019||September 30, 2021||September 30, 2021||March 6, 2019||July 8, 2019||
|2||NCT01236456||Withdrawn||High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy||
||25||All||18 Years to 75 Years (Adult, Older Adult)||NCT01236456||65865||October 2003||November 2006||November 8, 2010||August 12, 2011|
† Study has passed its completion date and status has not been verified in more than two years.